Alzheimer's disease (AD) is the most common cause of dementia in the elderly. The main hallmarks of this disease include progressive cognitive dysfunction and an accumulation of soluble oligomers of bamyloid (Ab) 1-42 peptide. In this research, we show the effects of lithium and memantine on spatial memory and neuroinflammation in an Ab1-42 oligomers-induced animal model of dementia in rats. Ab 1-42 oligomers were administered intrahippocampally to male wistar rats to induce dementia. Oral treatments with memantine (5 mg/kg), lithium (5 mg/kg), or both drugs in combination were performed over a period of 17 days. 14 days after the administration of the Ab1-42 oligomers, the radial arm-maze task was performed. At the end of the test period, the animals were euthanized, and the frontal cortex and hippocampus were removed for use in our analysis. Our results showed that alone treatments with lithium or memantine ameliorate the spatial memory damage caused by Ab1-42. The animals that received combined doses of lithium and memantine showed better cognitive performance in their latency time and total errors to find food when compared to the results from alone treatments. Moreover, in our study, lithium and/or memantine were able to reverse the decreases observed in the levels of interleukin (IL)-4 that were induced by Ab1-42 in the frontal cortex. In the hippocampus, only memantine and the association of memantine and lithium were able to reverse this effect. Alone doses of lithium and memantine or the association of lithium and memantine caused reductions in the levels of IL1b in the frontal cortex and hippocampus, and decreased the levels of TNF-a in the hippocampus. Taken together, these data suggest that lithium and memantine might be a potential therapy against cognitive impairment and neuroinflammation induced by Ab1-42, and their association may be a promising alternative to be investigated in the treatment of AD-like dementia.
Introduction
Alzheimer disease (AD) is the most common cause of dementia in the elderly. It is characterized by progressive cognitive impairments, including impaired judgment, decision-making and orientation, which are further combined with a severe loss of memory, in particular the loss of episodic and spatial memory (AlescioLautier, Michel, Herrera, et al., 2007; Galimberti & Scarpini, 2012; Laferla & Green, 2012) . The neuropathological hallmarks of AD include the accumulation of b-amyloid peptide 1-42 (Ab ) in the form of extracellular plaque, intraneuronal neurofibrillary tangles of hyperphosphorylated tau protein, exacerbated responses from glial cells with the overproduction of inflammatory cytokines, glutamatergic excitotoxicity, and neuronal and synaptic loss (Da Mesquita, Ferreira, Sousa, et al., 2016; Haass & Selkoe, 2007; Hu, http://dx.doi.org/10.1016/j.nlm.2017.03.017 1074-7427/Ó 2017 Elsevier Inc. All rights reserved. Ondrejcak, & Rowan, 2012; Serrano-Pozo, Frosch, Masliah, et al., 2011) .
Ab peptides are products of the proteolytic cleavage of amyloid precursor protein (APP) in the amyloidogenic pathway via the consecutive actions of b-and c-secretase (Haass, 2004) . In AD, there is an increase in the number of these cleavages which leads to an abnormal extracellular accumulation of Ab peptides, forming Ab oligomers and senile plaques, which may result in the loss of synaptic function and neuroinflammation (Browne, McQuillan, McManus, et al., 2013; Haass, Kaether, Thinakaran, et al., 2012) .
Currently, the pharmacotherapy of AD includes cholinesterase inhibitors (donepezil, galantamine, rivastigmine and tacrine) and memantine, which is an N-Methyl-D-aspartate (NMDA) receptor antagonist (Chong, Loi, & Lautenschlager, 2016; Johnson & Kotermanski, 2006; Qaseem, Santaguida, Ismaila, et al., 2008; Salloway & Correia, 2009) . Memantine decreases the level of cognitive decline in AD patients in the moderate to severe stages, since it reduces the amount of glutamatergic overstimulation, which is named excitotoxicity. In turn, this reduces the levels of neuronal damage and alleviates the symptoms of the disease (Reisberg, Doody, Stöffler, et al., 2003; Robinson & Keating, 2006) . However, while these therapies help to maintain neuronal function, they do not provide a significant impact on the reversal of the disease process (Geldmacher, 2003; Raina, Santaguida, Ismaila, et al., 2008) .
Therefore, it is necessary to investigate new therapeutic targets for AD. Amongst these potential targets is lithium. There is a growing body of evidence indicating that its neuroprotective effects may go beyond mood stabilization, and it is increasingly becoming implicated as a drug that may have beneficial effects against aging and neurodegenerative diseases such as AD (Camins, Verdaguer, Junyent, et al., 2009; Forlenza, De-Paula, & Diniz, 2014) .
Lithium protects neurons against the neurotoxic effects of Ab42 by favoring neurotrophic and neuroprotective responses (Alvarez, Muñoz-Montaño, Satrústegui, et al., 2002) . This drug is able to increase the levels of neurotrophins such as brain-derived neurotrophic factor (BDNF), which protects neurons against neurotoxic insults, stimulates hippocampal neurogenesis, increases synaptic plasticity and long-term potentiation (LTP) and positively regulates cell survival (Diniz & Teixeira, 2011) . Moreover, lithium inhibits glycogen synthase kinase-3 (GSK-3), inducing a decrease in proapoptotic activity (Chuang, 2005) . GSK-3 activity is involved in the physiopathology of AD (Machado-Vieira, Manji, & Zarate, 2009; Rybakowski, 2011) . Furthermore, lithium promotes hippocampal neurogenesis (Chen, Rajkowska, Du, et al., 2000; Fiorentini, Rosi, Grossi, et al., 2010) , besides providing neurons with protection against the excitotoxicity-induced apoptosis of NMDA receptors, preventing neuronal damage and tissue loss (Nonaka, Hough, & Chuang, 1998; Chalecka-Franaszek & Chuang 1999; Hashimoto, Fujimaki, Jeong, Christ, & Chuang, 2003; Bauer, Alda, Priller, et al., 2003) . Therefore, lithium could be an alternative when used in association with memantine, since memantine antagonizes NMDA receptors and lithium modulates the overstimulation of NMDA receptors (Camins et al., 2009; Sonkusare, Kaul, & Ramarao, 2005) . Lithium can also reduce the pro-inflammatory response (Forlenza et al., 2014) . It has been shown that treatment with lithium reduces both tissue damage and the levels of interleukin-1 beta (IL-1b) and tumor necrosis factor alpha (TNFa) production, which are induced by lipopolysaccharide in glial cells (Li, Li, Du, et al., 2011; Nahman, Belmaker, & Azab, 2012) and also in an animal model of sepsis (Albayrak, Halicia, Polatb, et al., 2013) .
Memantine, a drug that is widely used in the treatment of AD, was also shown to possess anti-inflammatory effects in preclinical (Chen, Tao, Chu, et al., 2013; Kahlfub, Narasimhulu, Mankiewicz, et al., 2014; Ma, Liu, Feng, et al., 2014; Wu, Tzeng, Qian, et al., 2009 ) and clinical studies (Lee, Chen, Chang, et al., 2014) . There is a growing body of evidence indicating that inflammation contributes to synaptic alterations, neuronal damage and subsequent cognitive impairments in the brains of AD patients. Accordingly, the use of drugs with anti-inflammatory effects is associated with a reduced risk or a delay in the progression of AD, thus, memantine is receiving much attention as a new therapeutic strategy in the treatment of AD (Aisen, 2002; Heneka, Kummer, Weggen, et al., 2011; Varvel, Bhaskar, Kounnas, et al., 2009; Yirmiya & Goshen, 2011) .
Therefore, the aim of this study was to evaluate the effects of lithium, memantine and a combination of lithium and memantine in the reduction of spatial memory loss and neuroinflammation induced by the intrahippocampal administration of Ab1-42 oligomer.
Material and methods

Animals
This study used a total of 80 adults male Wistar rats weighing between 280 g and 380 g. The animals were obtained from the vivarium of Universidade do Extremo Sul Catarinense (UNESC), and kept in cages on a 12-h light/dark cycle, with food and water available on demand. The temperature was maintained at 22 ± 1°C. All experimental procedures were performed according to the guidelines of the National Council of Animal Experimentation Control (CONCEA): the CONCEA guidelines for the practice of euthanasia, and the Brazilian Guidelines for the care and use of animals for scientific and educational purposes. The project was approved by the Ethics Committee on Animal Use (CEUA): UNESC 024/2015-1.
Stereotactic surgery for the induction of an animal model of dementia
Considering that the hippocampus is one of the brain structures responsible for episodic and semantic declarative memories, and that AD involves the loss of this memory (Leifer, 2009; Pasquier, Grymonprez, Lebert, et al., 2001) , it was decided that the Ab1-42 oligomers should be administered directly to the hippocampus by implanting cannulae guides through stereotactic surgery. Adult male Wistar rats (100-120 days old) were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) intraperitoneally, and placed in the stereotaxic apparatus. A1 cm incision was made in the skin of the animal's head to expose the cranial bone. Subsequently, a light scraping was performed with hydrogen peroxide 10V to display the bregma. Measurements were then performed to locate the hippocampus. After the coordinates of the hippocampus were located, a carbide surgical skull drill was used to pierce the skull. To induce the features of the dementia pathogenesis in the animals, each animal was administered with 2 lL of Ab1-42 oligomers (100 pmol/lL) bilaterally on the dorsal hippocampus, the total volume administered being 4 lL (400 pmol), via a cannula guide (incisor bar set at 1.2 mm lateral, 2.0 mm posterior to bregma, 3, 9 mm ventral) (Christensen, Marcussena, Wörtweinb, et al., 2008) . After the surgery, the animals were kept in a warm place with an electric heater to recover from the anesthesia.
Sub-chronic treatment
The Ab1-42 peptide (Tocris Bioscience, Bristol, UK) was dissolved in PBS solution (137 mM NaCl; 10 mM Na2HPO4; 1.8 mM KH2PO4; 2.7 mM KCl; pH 7.5) at a concentration of 1 mg/mL, then incubated for 7 days at 37°C to allow for the formation of birefringent fibril-like structures (oligomers Ab) (Christensen et al., 2008; Resende, Ferreiro, Pereira, et al., 2008; Ruiz-Muñoz, NietoEscamez, Aznar, et al., 2011; Ueda, Fukui, & Kageyama, 1994) . It was then stored at À20°C until use, and freshly diluted to the final dose of 400 pmol/site in ACSF (24 mM NaCl; 2.5 mM KCl; 2.0 mM MgSO 4 ; 1.25 mM KH 2 PO 4 ; 26 mM NaHCO 3 ; 10 mM glucose; 4 mM sucrose). One day after the intrahippocampal administration of Ab1-42 or ACSF the animals began receiving treatment with lithium carbonate (Carbolitium Ò , Eurofarma; Brazil) (5 mg/kg) (Zhao, Gongb, Liuc, et al., 2014) and memantine hydrochloride (Alois Ò , Apsen; Brazil) (5 mg/kg), orally by gavage (Liu, Wang, Yao, et al., 2014) . The control group (ACSF) received water (ACSF + water), lithium (ACSF + lithium), memantine (ACSF + memantine) or lithium and memantine associate (ACSF + lithium + memantine), and the AD-model group (Ab 1-42) received water (Ab 1-42 + water), lithium (Ab 1-42 + lithium), memantine (Ab 1-42 + memantine) or a combination of lithium and memantine (Ab 1-42 + lithium + memantine). The drugs were crushed and diluted in tap water, then administered orally with the aid of a special needle and syringe gavage at a volume of 1 mL/kg of animal body weight, over a period of 17 days. 24 h after the last dose, the animals were subjected to euthanasia.
Behavioral test
Octagonal maze (Radial arm-maze)
The octagonal maze apparatus has eight arms that radially extend from a central area, with geometric figures placed at the end of the arms in slopes 1, 3, 5 and 7, corresponding to the arms where the rewards were placed. Thus, on the 14th day of treatment, each animal was placed in the apparatus for a period of 10 min to get used to the apparatus. They were then returned to their housing box, where the animals were kept on a restricted diet and their body weight was maintained at 85% of their free-feeding weight over a period of one week, with water being available ad libitum. The following day corresponding to the 15th day of treatment, the animals were once again placed in the apparatus, but a reward (chocolate cereal) was placed in four of the eight arms of the maze, as previously mentioned. After finishing the task, the animals were removed from the apparatus and returned to their housing box. The same procedure was undertaken on the 16th, 17th and 18th days of treatment. This behavioral test was used to evaluate the spatial memory of the animals. During the 10 min test periods, the animals entry into each arm (total errors to find food) and the time each animal took to find the 4 cereal rewards was noted (latency to find food). The same details were recorded over the four consecutive test days, with 1 trial per day. The number of working memory errors (entering an arm containing food, which had previously been entered) and reference memory errors (entering an arm that was not baited) were measured (Foyet, Hritcu, Ciobica, et al., 2011; Hritcu, Cioanca, & Hancianu, 2012) . After the last test, and 24 h after the last administration of drugs, the animals were subjected to euthanasia.
Cytokine dosage by enzyme immuno assay (ELISA)
The levels of IL-4 (DY504), IL-1b (DY501) and TNF-a (DY510) were measured using ELISA kits from R&D Systems (DuoSet) according to the manufacturer's instructions. The frontal cortex and hippocampus from animals within each experimental group (n = 5-6) were homogenized with PBS, and centrifuged at 4°C for a period of 10 min at 10.000 rcf. PBS was added to the supernatant at a ratio of 1:1. To perform the assay, microliter plates (96 flat bottom wells) were incubated overnight with the capture antibody. Subsequently, the plates were washed three times with wash buffer (PBS with 0.05% Tween 20), and then the plates were blocked with 1% albumin in PBS for 1 h. The standard and homogenized samples were then incubated on a heated plate for 2 h. Subsequently, the plates were washed another three times with wash buffer, and then the plates were incubated with the detection antibody for a period of 2 h. After being washed, the plates were incubated streptavidin conjugated to peroxidase for a period of 20 min in a dark room at room temperature. Lastly, the substrate for peroxidase enzyme (hydrogen peroxide and tetramethylbenzidine) was incubated for 20 min and the stop solution was added (sulfuric acid 2 N), with the plates then being developed at 450 nm. All samples were measured in duplicate, with results expressed as picogram per milligram of protein and adjusted according to the protein content determined by Lowry, Rosebrough, Farr, et al. (1951) .
Statistical analysis
The results were analyzed using version 8 of the STATISTICA software (StatSoft, Inc., USA). The Shapiro-Wilk normality test was conducted to confirm that the data had a normal distribution. Mauchly's test of sphericity (assumption of violated sphericity) was also used, and repeated measures of two-way analysis of variance were used to assess the radial arm-maze task data followed by post hoc Duncan testing when p < 0.05. Data are presented as mean ± standard error of the mean. Data from the ELISA evaluation were analyzed by two-way ANOVA followed by the post hoc Duncan test when p < 0.05.
Results
Our results showed that there was a statistical difference when observing the latency to find the food, with an interaction observed between the administration of Ab1-42 and treatment [F (3, 70) = 2.36, p < 0.01], and the same interaction was observed in the total errors to find the food [F (3, 70) = 3.30, p < 0.05]. The animals that received Ab 1-42 presented with spatial memory impairment when observing the latency time to find food, when compared to the control group (ACSF + water) in the 2nd (p < 0.005), 3rd and 4th (p < 0.001) days of testing (Fig. 1A) . The same was observed in the results for total errors to find the food, where the animals from the control group (ACSF + water) had less mistakes than the Ab1-42 group (Ab 1-42 + water) on the 1st : p < 0.05, 2nd : p < 0.05, 3rd : p < 0.001 and 4th : p < 0.05 days of testing (Fig. 1B) . However, when the animals that received Ab1-42 were treated with lithium, they showed reduced latency times and errors to find food on the 2nd (latency and errors: p < 0.001), 3rd (latency: p < 0.05; errors: p < 0.001) and 4th (latency: p < 0.05; errors: p < 0.05) days compared to the 1st day. The group that received Ab1-42 which was treated with memantine was observed to have a reduction in latency and errors to find food only in the 3rd (latency: p < 0.0001; errors: p < 0.01) and 4th days (latency: p < 0.0001; errors: p < 0.01) when compared to the 1st day. When lithium and memantine were given in combination, the animals were faster on the 1st day when compared with Ab 1-42 that received no treatment (latency: p < 0.05; errors: p < 0.01), 2nd (latency: p < 0.05; errors: p < 0.01), 3rd (latency: p < 0.05; errors: p < 0.001) and 4th (latency: p < 0.05; but not errors p = 0.07) days. Therefore, lithium and memantine given alone were able to improve spatial memory impairments caused by Ab 1-42 oligomers. However, the combination of lithium and memantine appears to provide better results than the single treatments, as observed on the 2nd day, where the animals showed a reduction in latency and errors when compared to the Ab 1-42 group. Furthermore, on the 1st day of testing, the animals learned the task faster, showing a better level of cognitive performance.
When comparing reference memory errors ( Fig. 2A) , it was observed that there was an interaction between the administration of Ab1-42 and treatment [F (3, 70) = 4.44, p < 0.005]. The administration of Ab1-42 oligomers caused spatial memory impairments when compared to the last test day within the control group (p < 0.001). Lone treatments with lithium and memantine were able to reverse the observed damage (p < 0.005) but even more significant were the results for the drugs given in association (p < 0.0001). In addition, when comparing working memory errors (Fig. 2B) , it was found that there was an interaction between the administration of Ab1-42 and treatment [F (3, 70) = 3.77, p < 0.05]. On the 4th day, it was observed that the animal model of dementia group returned more often to the arms in which they had already consumed the reward, when compared with the control group (p < 0.05), the group treated with memantine (p < 0.05) and even more significantly with the group that received the combination of lithium and memantine (p < 0.001). Therefore, lithium and memantine were able to improve the impairments in reference memory caused by Ab 1-42 oligomers. Memantine was able to improve the impairments in working memory, however, the combination of lithium and memantine appears to be better than any of the single treatments, and was more statistically significant than the results for lone treatments.
The levels of IL-4 in the frontal cortex were analyzed (Fig. 3A) , and it was observed that there was an interaction between the administration of the Ab 1-42 oligomers and the treatments [F Figure (A) shows the latency to find the food in seconds and figure (B) shows the total error made by animals to find the food. Data were analyzed by repeated measures ANOVA, followed by the Duncan post hoc test. The data are expressed as mean ± standard error of mean for 9-11 animals per group, *p < 0.05 when compared to the first day of testing for the respective group, # p < 0.05 when compared to the Ab1-42 + water group in the respective day testing and $p < 0.05 when compared to the ACSF + water group in the respective day testing. (3, 25) = 9.07, p < 0.001], which reduced the levels of IL-4 when compared to the control group (p < 0.01). Lithium (p < 0.05), memantine (p < 0.0001), and the combined treatment (p < 0.0001) were able to reverse this effect. Moreover, memantine and the combined treatment showed higher levels of IL-4 than the control group (p < 0.05). In addition, in the hippocampus (Fig. 3B) , we observed an interaction between the administration of Ab1-42 and treatments [F (3, 25) = 8.94, p < 0.001], with the administration of Ab1-42 also reducing the levels of IL-4 (p < 0.05). However, only treatment with memantine (p < 0.001) or with the combination of lithium and memantine (p < 0.001) reversed this effect. When the levels of IL-1b (Fig. 4A ) within the frontal cortex were evaluated, it was observed that there was an interaction between the administration of the Ab1-42 oligomers and treatment [F (3, 24) = 2.88, p < 0.05]. Thus, the animal model of dementia group had an increase of this cytokine when compared to the control group (p < 0.01), and this increase was reversed by treatment with lithium (p < 0.05), memantine (p < 0.001) and the combination of both drugs (p < 0.001). These last two treatments reduced the levels of this cytokine to lower levels than seen in the control group (p < 0.05). The levels of IL-1b in the hippocampus (Fig. 4B ) also showed an interaction [F (3, 28) = 2.86, p < 0.05]. The administration of Ab1-42 oligomers increased the levels of IL-1b when compared to the control animals (p < 0.05), and treatments with lithium, memantine, and the combination of both reversing this effect (p < 0.001).
In addition, the levels of TNF-a in the frontal cortex were also analyzed (Fig. 5A) , and showed no interaction [F (3, 28) = 0.38, p = 0.76], and there was no difference between any of the groups. However, the levels of this cytokine in the hippocampus (Fig. 5B) showed an interaction [F (3, 25) = 3451, p < 0.05]. Moreover, the administration of the Ab1-42 oligomers did not induce an increase in the levels of TNF-a when compared to the control animals (p = 0.45). Nevertheless, treatment with lithium, memantine and the combination of both were able to reduce the levels of this cytokine in the control group (p < 0.001) and in the animals, that were administered with Ab1-42 (p < 0.001).
Discussion
Considering that cognitive decline and the deficit of visuospatial memory are both clinical symptoms of AD (Alescio-Lautier et al., 2007) , and the deficit of learning and spatial memory have been reported in studies with transgenic mice in the APP/PS1 model (Kiyota, Okuyama, Swan, et al., 2010; Morgan, Diamond, Gottschall1, et al., 2000) ; the present study used intrahippocampal administrations of Ab1-42 oligomers in rats to induce spatial memory impairment. The Ab oligomer causes toxicity to the cells, inducing cognitive impairment in both humans and rodents (Herrup, 2010; Johnson, Fox, Sperling, et al., 2012) . The deposit of Ab is the most pathological feature of AD (Johnson et al., 2012) . Therefore, the administration of Ab oligomers is used as an ADlike model of dementia in rodents, since it induces damage to the process of learning and memory (Shankar, 2008; Pozueta, Lefort, & Shelanski, 2013) .
The effects of lithium as observed in the preset study corroborate the findings in literature that show it possesses a possible protective role against cognitive decline. A preclinical study using APP/ PS1 transgenic mice showed that chronic treatment with low doses of lithium could reverse spatial memory impairments, being effective in improving learning, consolidation and memory retrieval (Nunes, Schöwe, Monteiro-Silva, et al., 2015) . Mury, Da Silva, Barbosa, et al. (2015) showed that lithium has a significant effect on the retention of long-term memory in Wistar rats. Additionally, a clinical study demonstrated the effect of lithium carbonate treatment in patients with AD, where it showed performance improvements in the mini mental state exam (MMSE) test (Nunes, Viel, & Buck, 2013) . Memantine is an approved drug under the FDA for the treatment of AD. In our study, memantine also showed a protective effect against cognitive impairments induced by Ab1-42 oligomers. Memantine treatment in APP/PS1 transgenic mice showed significant improvements for both learning and memory . In addition, another study has shown that treatment with memantine significantly reduced the levels of spatial memory damage in rats that were subjected to bilateral intracerebroventricular injections of streptozotocin, as evaluated in the Morris water maze test (Rai, Kamat, Nath, et al., 2013 ).
The present data shows that rats that received treatments combining lithium and memantine indicated better levels of cognitive performance in the radial arm-maze task than the rats from the groups that received treatment with memantine or lithium alone. Therefore, the association of lithium and memantine appears to be an alternative therapy that should be investigated for use in the treatment of cognitive impairments seen in AD. This approach is very valid within this work, because although memantine is approved by the FDA for the treatment of AD, it is not fully effective (Smith, 2009) . Therefore, we suggest there should be interest in investigating and applying associations of drugs involving memantine to enhance the therapeutic response in AD patients. Among these combinations is the association of memantine and acetylcholinesterase inhibitors (Gauthier & Molinuevo, 2013; Riverol, Slachevsky, & López, 2011) . The present study was the first to look at the combination of memantine and lithium, and our results highlight a promising combined therapy for the treatment of the cognitive impairments found in AD. More studies need to be undertaken to make these findings more robust.
The cognitive impairment found in AD can be partially explained by inflammation, which is one mechanism that contributes to the progression and development of AD (Heppner, Ransohoff, & Becher, 2015) . There is also an increase in the levels of cytokine which can be observed in the serum, brain and cerebrospinal fluid of patients suffering with AD (Jack, Knopman, Jagust, et al., 2013; Zhang, Miller, Madison, et al., 2013) . The present study showed that the administration of Ab1-42 oligomers in rats induced neuroinflammation, since it reduces the levels of IL-4 in the frontal cortex, and increases the levels of IL-b in the frontal cortex and hippocampus.
A study has shown that an increase in the levels of IL-4 improved spatial learning, reduced astrogliosis, microgliosis, Ab oligomerization and deposition, and enhanced neurogenesis in APP/PS1 transgenic mice (Kiyota et al., 2010) . In our study, lithium was able to reverse the decreases in the levels of IL-4 in the frontal cortex which were caused by the administration of Ab1-42. This finding had only previously been reported in an ex vivo assay undertaken on blood cultures. In this study, the monocytes in the presence of a mitogen exposed to lithium showed an increase in the levels of IL-4 production secreted by Th2 lymphocytes, and a reduction of the pro-inflammatory cytokines secreted by Th1 lymphocytes (Rapaport & Manji, 2001) . In the present study, memantine was able to increase the levels of IL-4 in the frontal cortex and hippocampus to higher levels than those seen in the control group. Other studies have shown the anti-inflammatory effects of memantine, which include; reductions in the chronic activation of microglial cells, lower levels of apoptosis, and consequently less neuronal loss in the CA1 region of the hippocampus (Hidalgo, Alvarez, Cacabelos, et al., 2002) . Another study has shown that in transgenic mouse T cell receptors undergoing treatment with memantine, there was a significant reduction in T cell proliferation directly proportional to the concentration used, including a strong inhibition of the proliferative response of CD4 + T cells and consequently a decrease in the secretion of cytokines (Kahlfub et al., 2014) . The association of lithium and memantine presented a similar result to lone treatments of memantine when assessing the levels of IL-4. Additionally, neuroinflammation also triggers the release of glutamate from microglia through the glutamate cystine transporter (xCT) (Barger, Goodwin, Porter, et al., 2007) . This glutamate release activates the NMDA receptor, causing overexcitation and apoptose. It was also demonstrated that IL-4 prevents glutamate release from microglia, suppressing the expression of xCT induced by Ab (Savchenko, 2013) . Therefore, the increase of IL-4 may be related to the inhibition of NMDA receptors caused by memantine. Moreover, chronic treatments with lithium chloride at subtherapeutic concentrations were able to modify the secretion of pro and anti-inflammatory interleukins in cultures of cortical neurons and glial cells from the hippocampus (De Paula, Kerr, Scola, et al., 2016) . In the present study, lithium reversed the increase in the levels of IL-1b that were observed in the dementia model group within the prefrontal cortex and hippocampus. The same result was observed in the rats treated with memantine. Moreover, lone treatments with lithium and memantine, or treatments with both drugs given in combination were able to reduce the levels of TNF-a in the hippocampus.
It was observed that a low dose of memantine significantly reversed the increases of IL-1b found in serum, which had been induced by morphine (Chen et al., 2013) . Treatment with memantine also caused a reversal of the increases in the levels of IL-1b and TNF-a in the hippocampus and cortex which were induced by streptozotocin (Rai et al., 2013) . A study involving patients suffering with bipolar disorder showed that the levels of TNF-a in serum were significantly lower in patients receiving treatments with memantine (Lee et al., 2014) . Pretreatment with memantine in mice attenuated acute lung injury induced by LPS, and reduced the levels of TNF-a in the bronchoalveolar lavage (Ma et al., 2014) . Corroborating these findings, our results show that memantine was able to reduce the levels of the pro-inflammatory cytokines IL-1b and TNF-a in the frontal cortex and hippocampus. Exogenous IL-1b and TNF-a causes increases in the frequency and amplitude of spontaneous excitatory postsynaptic current (EPSC) of NMDA-induced currents in dorsal horn neurons, suggesting these cytokines can enhance the release of glutamate from presynaptic neurons (Kawasaki, Zhang, Cheng, et al., 2008) . In addition, the chronic administration of NMDA increases the levels of IL-1b and TNF-a in rat frontal cortex, highlighting the cross-talk between excitotoxicity and neuroinflammation. Therefore, memantine and lithium combined or alone can reduce these cytokines (mainly IL-1b), in turn, reducing glutamate release and inducing neuroprotection. The anti-inflammatory effect of lithium has been observed in other studies. It has also been reported that lithium has an antiinflammatory effect in the glial cells of rats that have inflammation induced by LPS. Treatment with lithium in vitro reduced the production of IL-1b and TNF-a (Nahman et al., 2012) . The levels of IL-1b also increased due to stimulation with LPS in the monocytes of healthy patients, and treatment with lithium was able to restore these levels (Knijff, Breunis, Kupka, et al., 2007) . Another study observed that lithium reduced the levels of TNF-a, IL-1b and IL-6 in the serum of Wistar rats that were subjected to a puncture model of sepsis and cecal ligation with high levels of bacterial endotoxin (Albayrak et al., 2013) . In addition, mononuclear cells of human peripheral blood stimulated with agonist toll-like receptors in the presence of specific inhibitors of GSK-3 resulted in a very significant reduction in the production of the pro inflammatory cytokines IL-1b, IL-6 and TNF-a (Martin, Rehani, Jope, et al., 2005) . Lithium, an inhibitor of GSK-3, may suppress inflammation induced by LPS, reducing TNF-a production (Wang, Huang, Wang, et al., 2009) . Therefore, it is promising treatment with lithium by the interaction between their anti-inflammatory effects and inhibition of GSK-3, since inhibition of GSK-3 is one of its main mechanisms, and the inhibition of this protein leads to a reduction of tau hyperphosphorylation. In fact, a growing body of evidence strongly suggest that GSK3 is involved in AD through to modulate Ab production and tau phosphorylation (Cai, Zhao, & Zhao, 2012; Hong, Chen, Klein, et al., 1997; Phiel, Wilson, Lee, et al., 2003; Rockenstein, Torrance, Adame, et al., 2007; Small & Duff, 2008) .
Conclusion
The results indicate that sub chronic treatment with lithium or memantine reversed the damage to the spatial memory of the animals that were administered with Ab1-42 oligomers. In addition, the rats that were treated with the combination of lithium and memantine showed a better level of cognitive performance than those that were treated with memantine or lithium alone. Therefore, the association between lithium and memantine appears to be an alternative therapy for the treatment of cognitive impairment in AD, but this combination requires further investigation. However, the better cognitive performance seen in the radial arm-maze task which was observed in the rats that received the combination of lithium and memantine is not solely justified by the anti-inflammatory effect provided by the drugs, as although the association of memantine and lithium had an antiinflammatory effect against the toxicity caused by the Ab1-42 oligomers, the combination did not potentiate this effect. However, we cannot be ruled out that the mechanism of the association may involve, at least in part, the anti-inflammatory effect of memantine. According to the results, the contribution of lithium to the anti-inflammatory effect of the association appears to be small. Then, further studies are needed to investigate the putative mechanism of this association. Altogether, the results indicate that lithium and its association with memantine may be a future therapeutic treatment for AD.
